http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
-
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
-
BioStem Technologies Expands Product Access in Medicaid
-
BioStem Technologies files restated financial statements
-
BioStem Technologies Reports Third Quarter 2025 Financial Results
-
BioStem Technologies Announces Filing of Restated Financial Statements
-
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
-
BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025
-
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
-
BioStem Technologies to Present at Two Upcoming Investor Conferences
-
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
-
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
-
BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025
-
BioStem Technologies to Present at the Centri Capital Conference
-
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
-
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
-
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
-
BioStem Technologies CEO to Present at Biotech Showcase 2025
-
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
-
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
-
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
-
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
-
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
-
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
-
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
-
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
-
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
-
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
-
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
-
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
-
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
-
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
-
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
-
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
-
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
-
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference
-
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
-
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market
-
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
-
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role
-
BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors
-
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions
-
BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors
-
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results
-
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services
-
BioStem Technologies Closes Oversubscribed $2M Private Placement
-
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje(R) in Diabetic Foot Ulcers
